Y. Wang
Internal medicineRetrospective cohort studyMedical recordAdverse effectPatient safetyItchingMultiple sclerosisNatalizumabTreatment durationMedicine
Publications 1
#1Yujie WangH-Index: 1
Last. Annette WundesH-Index: 12
view all 7 authors...
Background: Natalizumab is an approved treatment for relapsing-remitting multiple sclerosis (RRMS) since 2006. Though infusion reactions are usually mild, occur typically within the first six months of treatment and clinically relevant infusion reactions are extraordinarily rare, there is a mandatory one-hour post-infusion monitoring after each dose, independent of treatment duration. This has posed concerns of unnecessarily increasing SARS-CoV2 exposure risks for patients and staff. Objectives:...